Esketamine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Esketamine: From Treatment-Resistant Depression to Agoraphobia
One-Sentence Summary
Esketamine is the S-enantiomer of ketamine, marketed internationally (as Spravato) for treatment-resistant depression (TRD). The TxGNN model’s top-ranked prediction for this compound is Agoraphobia, but this specific direction is currently supported by 0 clinical trials and only 1 indirect literature reference, placing it at the lowest tier of evidence maturity.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Treatment-resistant depression (per literature record; no formal local license on file) |
| Predicted New Indication | Agoraphobia |
| TxGNN Prediction Score | 99.57% |
| Evidence Level | L4 |
| EU Market Status | Not marketed (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on information present elsewhere in the evidence collected, Esketamine is the active ingredient of the nasal spray Spravato, an NMDA-receptor antagonist that modulates glutamatergic neurotransmission and produces rapid-acting antidepressant effects; it has established efficacy in treatment-resistant depression and is approved for that use in the US and EU.
Treatment-resistant depression and agoraphobia both fall within the broader mood/anxiety-disorder spectrum, and glutamatergic (NMDA) signaling has been implicated in fear-extinction and panic-circuit neurobiology in general anxiety research. This provides a plausible, though unproven, mechanistic bridge.
However, the only supporting literature retrieved is a general review of anxiety-disorder pharmacotherapy (panic disorder, GAD, social anxiety disorder) that does not specifically address agoraphobia or provide esketamine-specific efficacy data. No clinical trials in agoraphobia patients have been identified. The prediction should therefore be treated as a knowledge-graph-driven hypothesis rather than an evidence-backed clinical signal.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33424664 | 2020 | Review | Frontiers in Psychiatry | General review of current and emerging pharmacotherapy for anxiety disorders (panic disorder, GAD, social anxiety disorder); does not focus specifically on agoraphobia and provides no esketamine-specific clinical data |
EU Market Information
Esketamine is currently not marketed in this jurisdiction (0 marketing authorizations on record).
Safety Considerations
Please refer to the SmPC for safety information. (Key warnings, contraindications, and DDI data are all flagged as data gaps or not found in this evidence pack; TFDA label/warning retrieval is a Blocking-severity gap, DG001, required before any safety screening can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top TxGNN-ranked prediction (Agoraphobia) has no supporting clinical trials and only one indirect, non-specific literature review (L4 — mechanism/preclinical-tier evidence). Combined with the absence of local marketing authorization and two outstanding data gaps (TFDA label/warnings — Blocking; MOA — High), there is insufficient evidence to advance this candidate beyond hypothesis stage.
To proceed, the following is needed:
- Retrieve TFDA/SmPC label warnings and contraindications (DG001, blocking S1 safety screening)
- Confirm mechanism of action via DrugBank API (DG002)
- Identify or initiate clinical trials specifically evaluating esketamine in agoraphobia
- Obtain agoraphobia-specific literature beyond general anxiety-disorder reviews
- Drug-drug interaction (DDI) data, currently not found in queried sources
Note: This candidate’s evidence pack also contains other predicted indications (e.g., neurotic depression, rank 3) with substantially stronger clinical trial and literature support (L1, “Proceed with Guardrails”) largely reflecting esketamine’s already-approved TRD indication under a legacy diagnostic label — these may warrant separate review outside the scope of this agoraphobia-focused report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.